U.S. health officials revised the federal childhood immunization schedule, narrowing routine recommendations and moving several vaccines to risk‑based or shared‑decision categories. The Centers for Disease Control and Prevention and HHS implemented the change after an internal review intended to align U.S. guidance with practices in peer nations. Trade groups and industry leaders quickly voiced concern, warning the policy shift could undermine vaccine confidence and complicate manufacturer planning for pediatric markets. BIO issued a statement arguing that the change departed from a long-standing evidence-based process and could increase public confusion about immunization. The move also prompted legal and policy scrutiny and may influence vaccine developers’ commercial strategies and public‑health outreach efforts in the near term.